Literature DB >> 14763130

Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.

John Lyons1, Emel Bayar, Gil Fine, Michael McCullar, Randee Rolens, Joseph Rubinfeld, Craig Rosenfeld.   

Abstract

Decitabine (DAC) is a small molecule nucleotide analog that is incorporated into DNA and traps human DNA methyltransferases. Although initially developed as a cytotoxic agent, low-dose DAC is enjoying a revival as a specific inhibitor of hypermethylation in cancer. DAC has activity in several hematological diseases, especially myelodysplastic syndrome, chronic myelogenous leukemia and acute myeloid leukemia. Clinical and preclinical advances are presented in this review.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14763130

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.

Authors:  Benigno C Valdez; Yang Li; David Murray; Paul Corn; Richard E Champlin; Borje S Andersson
Journal:  Leuk Res       Date:  2009-09-03       Impact factor: 3.156

3.  Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.

Authors:  G Nicolas Batty; Hagop Kantarjian; Jean-Pierre Issa; Elias Jabbour; Fabio P S Santos; Deborah McCue; Guillermo Garcia-Manero; Sherry Pierce; Susan O'Brien; Jorge E Cortés; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-06

4.  Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Authors:  Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Journal:  DNA Repair (Amst)       Date:  2009-10-15

5.  A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.

Authors:  Pilar Zambrano; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucely Cetina; Alma Revilla-Vazquez; Lucía Taja-Chayeb; Alma Chavez-Blanco; Enrique Angeles; Gustavo Cabrera; Karina Sandoval; Catalina Trejo-Becerril; Jose Chanona-Vilchis; Alfonso Duenas-González
Journal:  BMC Cancer       Date:  2005-04-29       Impact factor: 4.430

6.  The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Authors:  I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

7.  Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.

Authors:  Mika Hosokawa; Mai Saito; Aiko Nakano; Sakura Iwashita; Ayano Ishizaka; Kumiko Ueda; Seigo Iwakawa
Journal:  Oncol Lett       Date:  2015-05-22       Impact factor: 2.967

8.  Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.

Authors:  Hua Xiong; Zhao-Fei Chen; Qin-Chuan Liang; Wan Du; Hui-Min Chen; Wen-Yu Su; Guo-Qiang Chen; Ze-Guang Han; Jing-Yuan Fang
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.